Humidified high flow therapy system

myAirvo™ 2

Deliver humidified high flows from 2-60 L/min to chronic respiratory patients at home or in long-term care facilities.

F&P myAIRVO™ 2 Humidifier

The F&P myAIRVO 2 has been designed specifically to be a solution for delivering the benefits of humidification and flow to patients in the home and in long-term care. Fisher & Paykel Healthcare’s leading humidification technology allows the myAIRVO 2 to comfortably provide high flows of air/oxygen mixtures to spontaneously breathing patients, through the unique Optiflow nasal cannula interface or tracheostomy interfaces available.

Advanced Humidity Algorithm

The myAirvo 2 algorithm’s intelligent controls deliver Optimal Humidity to patients at 37, 34 or 31 °C.

myAirvo™ 2 Air Pathway

A uniquely designed air pathway thoroughly conditions the mix of air and oxygen to accurately deliver the patient’s set flow rate.

AirSpiral™ Tube

The two-spiral design produces up to 93% less condensate*, maximizing humidity levels of the breathing gas.

*When compared with Airvo tube 900PT501 in internal F&P testing

The myAirvo™ 2 generates high flows of warmed and humidified respiratory gases, delivered to the patient through a variety of nasal, tracheostomy and mask interfaces.

The AIRVO device is a flow source with an integrated heated humidification system able to deliver 15 to 60 LPM of respiratory gas humidified to close to 100% relative humidity.

This high flow device provides a prescribed flow of humidified gas (air or air and oxygen as required) to a patient. The flow is provided to the patient via nasal cannula or tracheostomy interfaces.

AIRVO is designed to treat respiratory conditions that impede a patient’s ability to breathe and successfully manage their secretions.

Benefits of Nasal High Flow:

Comfortable oxygen delivery, reducing the likelihood of treatment failure.
Reduce rebreathing of expired CO₂
Delivery of Dynamic Positive Airway Pressure
Optimize mucociliary clearance
Can continue to eat, drink, talk and sleep
May displace the need for noninvasive or invasive ventilation through better patient tolerance
Improved respiratory efficiency
Significantly fewer exacerbation day; 18.2 versus 33.5 days
Increase days to first exacerbation 27 days to 52 days
Significantly improve FEV1 and FVC %
Reduce antibiotic use
Promotes slow, deep breathing while increasing alveolar ventilation and having a positive impact to work of breathing

The results speak for themselves.

The F&P Solo mask combines years of innovation, premium materials and cutting-edge components so users
can set themselves up without assistance and easily fine-tune their mask fit throughout the night.

Simple adjustable temperature and flow settings

• Three temperature settings (37, 34, 31 °C) help achieve comfort and compliance.
• Integrated flow generator delivers a wide flow range (2 – 60 L/min) – no wall air supply required.

Supplementary oxygen (when required)